Navigation Links
DURECT Corporation Announces Third Quarter 2012 Financial Results and Update of Programs
Date:11/5/2012

CUPERTINO, Calif., Nov. 5, 2012 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2012. Total revenues were $3.8 million for the three months ended September 30, 2012 as compared to $8.1 million for the three months ended September 30, 2011.  Net loss for the three months ended September 30, 2012 was $4.8 million, compared to a net loss of $5.0 million for the same period in 2011.

(Logo:  http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)

At September 30, 2012, we had cash and investments of $21.0 million, compared to cash and investments of $23.7 million at June 30, 2012 and $30.8 million at December 31, 2011.  We have no debt obligations, other than normal liabilities associated with running our business."Following our pre-NDA communications with the FDA this summer, we are preparing to submit a new drug application for POSIDUR in the first quarter of 2013," stated James E. Brown, D.V.M., President and CEO of DURECT.  "Pfizer has initiated a confirmatory bioavailability study to assess the pharmacokinetic profile of modified REMOXY formulation compositions, with a data read out expected early in 2013.  We also are pleased that Zogenix has been actively enrolling in the Phase I clinical trial for Relday."

Update of Programs:

  • REMOXY® (oxycodone) Extended-Release Capsules CII.  Pfizer has efforts underway to resolve the issues raised in the REMOXY Complete Response Letter and stated in their quarterly earnings call on November 1, 2012 that they have initiated a confirmatory bioavailability study to assess the pharmacokinetic profile of modified REMOXY formulation compositions, with data expected in early 2013.  Pfizer expects that the results of this study wi
    '/>"/>

    • SOURCE DURECT Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. DURECT Corporation Invites You to Join its Third Quarter 2012 Earnings Conference Call
    2. DURECT to Participate in Upcoming Healthcare Conferences
    3. DURECT Corporation Announces Second Quarter 2012 Financial Results and Update of Programs
    4. DURECT Corporation Announces First Quarter 2012 Financial Results and Update of Programs
    5. DURECT Announces Issuance of U.S. Patents Covering ORADUR® Technology
    6. Psychemedics Corporation Announces 3rd Quarter Earnings
    7. RayBiotech, Inc. and Abeome Corporation Announce an Agreement Related to Novel Research Products for Ovarian Cancer
    8. CombiMatrix Corporation Selects Cartagenia BENCHlab CNV Platform to Bolster Expanded Lab Operations
    9. United Therapeutics Corporation Reports Third Quarter 2012 Financial Results
    10. Fish & Richardson Prevails in Patent Infringement Trial for Volcano Corporation
    11. Luminex Corporation Reports Third Quarter 2012 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/23/2013)... , May 23, 2013  Inhibikase Therapeutics, Inc., ... today that it will present new results on ... industry conference sponsored by the PML Consortium (composed ... JC polyomavirus (JCV) is the causative agent of ... kinase inhibitor in an extended release formulation, can ...
    (Date:5/23/2013)... 23, 2013  PAREXEL International Corporation (NASDAQ: ... at the Jefferies Healthcare Conference in New York.  ... Chief Financial Officer, will be making a presentation on ... Monday, June 3, 2013. A live webcast ... section of PAREXEL,s website at www.PAREXEL.com in ...
    (Date:5/22/2013)... , May 22, 2013  Aribex, Inc., manufacturer ... system, today introduced a new color option, black with ... U.S. dental and veterinary markets. The popular white with ... month will continue to be available and both models ... (Photo: http://photos.prnewswire.com/prnh/20130522/CL19573 ) ...
    Breaking Medicine Technology:Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML) 2PAREXEL International To Present At Jefferies Healthcare Conference 2Aribex Unveils New Color of NOMAD Pro 2 2
    ... 2011  Proventix Systems, Inc., today announced its nGage™ ... hand hygiene monitoring system in the United States.  ... total hand cleansings. Hospitals have experienced ... dispenses since implementation of the Proventix monitoring system. ...
    ... brings a whole set of skin problems for many people, ... Americans who suffer from psoriasis. Cold weather, dry indoor heat, ... rob the skin of the moisture it needs, causing psoriasis ... system, making it harder for the body to resist psoriasis ...
    Cached Medicine Technology:Proventix's nGage™ the Most Widely Used Automated Healthcare Hand Hygiene Monitoring System in the United States 2Proventix's nGage™ the Most Widely Used Automated Healthcare Hand Hygiene Monitoring System in the United States 3PhotoMedex Helps Psoriasis Patients Ease Winter Skin Care Woes 2PhotoMedex Helps Psoriasis Patients Ease Winter Skin Care Woes 3PhotoMedex Helps Psoriasis Patients Ease Winter Skin Care Woes 4
    (Date:5/23/2013)... May 23, 2013 NDI Medical, ... and develops innovative neurodevice technologies, has launched its ... DBI will commercialize its groundbreaking technology that ... therapy for patients with Parkinson’s disease. Currently ... disease and generates more than $275 million in ...
    (Date:5/23/2013)... PETA International Science Consortium, Ltd., issued the following ... of 2013: , Reform of chemical safety legislation ... testing. , Ensuring the safety and appropriate ... Reforming the EPA,s Toxic Substances Control Act is ... Council,s vision for transforming toxicity testing "from a ...
    (Date:5/23/2013)... Dotinga HealthDay Reporter , , WEDNESDAY, May 22 (HealthDay ... scans for detecting lung cancer now have more information to ... U.S. study finds that low-dose CT scans pick up significantly ... a long history of smoking are at high risk for ... States. But doctors have to consider the potential harm of ...
    (Date:5/23/2013)... In Florida, residents have not been hit with a ... Florida’s good luck will continue, warns Rick Knabb, Director of ... residents, it is important to prepare as if one could ... to be a 50-percent chance that a major hurricane could ... from June 1 to November 30 in Florida, this makes ...
    (Date:5/23/2013)... Award-winning parent coaching and training ... ImpactADHD’s six-part Parent Academy Mastery Series gives families ... challenges of raising ADHD kids head-on. Parenting kids ... frustrating. It can also be joyful and positively ... and the ‘good stuff’ is all-too-often out of ...
    Breaking Medicine News(10 mins):Health News:NDI Launches Deep Brain Innovations, LLC 2Health News:NDI Launches Deep Brain Innovations, LLC 3Health News:CT Scans Reduce Lung Cancer Deaths, Study Confirms 2Health News:CT Scans Reduce Lung Cancer Deaths, Study Confirms 3Health News:As Hurricane Season Nears, Skylake Insurance Encourages Florida Residents To Prepare Early For Safety 2Health News:New Approach to ADHD Managment Focuses On Parents, Not Kids 2
    ... while sticking to your diet. Here,s how. , FRIDAY, Dec. 25 ... you,ve eaten and that box of Santa Claus-shaped candies is calling ... overeat and overindulge aren,t over yet. , Before you take one ... to get a handle on your holiday eating. , If you,ve ...
    ... how product is designed, study shows , THURSDAY, Dec. ... everything from promoting youth violence to contributing to childhood obesity, ... planned on passing by the video game aisle this holiday ... can sharpen certain thinking skills, increasing cognitive speed in those ...
    ... Dec. 24 Today, The U.S. Conference of Mayors (USCM) congratulates ... health care for millions of the uninsured. In a historic ... the Patient Protection and Affordable Care Act. , "Not ... on Christmas Eve. It is appropriate the most important ...
    ... THURSDAY, Dec. 24 (HealthDay News) -- Acetaminophen -- best ... physical pain, but a new study suggests that the ... of rejection. , Researchers assigned 62 healthy college undergraduate ... 1,000 milligrams of acetaminophen daily, while the others took ...
    ... , ... (PhRMA) Senior Vice President Ken Johnson released the following statement ... the Senate for taking an important and historic step toward ... of millions of Americans, many of whom are struggling today ...
    ... , , WASHINGTON, Dec. 24 ... Senate voted to pass the Patient Protection and Affordable Care ... bill on Christmas Eve, after overcoming a series of procedural ... stop the bill from ever reaching the Senate floor for ...
    Cached Medicine News:Health News:Eat Up, But Eat Healthy This Holiday Season 2Health News:Video Games Could Boost Certain Thinking Skills 2Health News:Video Games Could Boost Certain Thinking Skills 3Health News:Tylenol May Ease Headaches and Heartaches 2Health News:Tylenol May Ease Headaches and Heartaches 3Health News:PhRMA Statement on Senate Health Care Reform Bill 2Health News:PhRMA Statement on Senate Health Care Reform Bill 3Health News:DNC Chairman Tim Kaine Calls Senate Vote Historic, Says Landmark Health Reform Bill Is a Victory for the American People 2
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    Medicine Products: